Chesapeake PERL Inc.
This article was originally published in Start Up
Executive Summary
Cell culture is the widely accepted and proven methodology for manufacturing recombinant proteins but it can be costly, time-consuming, and inflexible. Chesapeake PERL Inc. (C-PERL)--short for protein expression and recovery labs--is hoping to change this: its mission is to manufacture proteins inexpensively and quickly so it can serve as a contract manufacturer for biopharmaceuticals, especially small-to-midsize firms that require the flexibility of swiftly switching between producing quantities of protein A to protein B.
You may also be interested in...
Protein Production Start-Ups
Should a disruptive protein production technology emerge, the current interest in developing large-molecule therapeutics assures there would be many takers.
Which Private Investors are Cashing Out?
Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.
What Entrepreneurs Want, Get, and Don't Get from VCs
What makes a health care VC stand out in the minds of entrepreneurs? According to a first-of-its-kind survey by Windhover, PricewaterhouseCoopers, Wilson Sonsini, and Applied Information Networks, the answer is value-added services. Entrepreneurs prize VCs who assist them, pre-financing, with constructive feedback and sharing of due diligence results. VCs do pretty well here. But they do less well on the more important post-financing criteria: helping their portfolio companies secure additional financing and recruit customers, partners, and employees.